InMode (INMD) Projected to Post Quarterly Earnings on Wednesday

InMode (NASDAQ:INMD - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Wednesday, July 30th. Analysts expect InMode to post earnings of $0.50 per share and revenue of $98.45 million for the quarter.

InMode (NASDAQ:INMD - Get Free Report) last released its earnings results on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.14). The company had revenue of $77.87 million during the quarter, compared to analysts' expectations of $82.21 million. InMode had a return on equity of 17.17% and a net margin of 44.79%. InMode's quarterly revenue was down 3.0% compared to the same quarter last year. During the same period last year, the firm posted $0.32 EPS. On average, analysts expect InMode to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

InMode Stock Up 1.3%

InMode stock traded up $0.19 during mid-day trading on Friday, reaching $14.72. 632,206 shares of the company's stock traded hands, compared to its average volume of 1,619,674. The company has a market cap of $930.45 million, a price-to-earnings ratio of 6.32 and a beta of 1.95. The stock has a 50 day moving average of $14.37 and a two-hundred day moving average of $16.04. InMode has a 12-month low of $13.14 and a 12-month high of $19.85.

Institutional Investors Weigh In On InMode

Several large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its position in InMode by 234.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company's stock worth $19,935,000 after acquiring an additional 788,157 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of InMode during the first quarter valued at $317,000. Finally, Royal Bank of Canada boosted its stake in InMode by 5.7% in the 1st quarter. Royal Bank of Canada now owns 242,398 shares of the healthcare company's stock worth $4,299,000 after buying an additional 13,032 shares during the last quarter. 68.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on INMD shares. Barclays cut their price target on shares of InMode from $29.00 to $24.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. BTIG Research downgraded shares of InMode from a "buy" rating to a "neutral" rating in a research note on Tuesday, April 29th. Baird R W lowered shares of InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Robert W. Baird lowered shares of InMode from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $22.00 to $16.00 in a research report on Monday, April 28th. Finally, UBS Group cut their target price on shares of InMode from $19.00 to $16.25 and set a "neutral" rating for the company in a report on Tuesday, April 29th. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $18.54.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.